Prognostic Role of Human Epidermal Growth Factor Receptor 2 Status in Premenopausal Early Breast Cancer Treated With Adjuvant Tamoxifen.

CONCLUSIONS: Resistance to tamoxifen is a complex trait, and its pathway is still unclear; in patients with BC, a multidisciplinary approach is highly recommended. In our experience, we did not find a statistically significant difference in tamoxifen treatment efficacy according to HER2 status.
PMID: 23684167 [PubMed - as supplied by publisher]

Source: Clinical Breast Cancer - May 14, 2013 Category: Cancer & Oncology Authors: Meattini I, Livi L, Saieva C, Franceschini D, Scotti V, Mangoni M, Loi M, Brina LD, Zei G, Bonomo P, Greto D, Gelain E, Nori J, Sanchez LJ, Orzalesi L, Bianchi S, Biti G Tags: Clin Breast Cancer Source Type: research